BreezeBio (formerly GenEdit)
BreezeBio, Inc. (formerly GenEdit) is a clinical-stage genetic medicines company based in South San Francisco, California, solving the central delivery problem of gene editing and genetic medicine. Its proprietary NanoGalaxy platform is a library of thousands of non-viral, non-lipid polymer nanoparticles engineered to deliver genetic payloads (mRNA, DNA, and CRISPR ribonucleoprotein) to specific cell types and tissues without triggering an immune response. The company is advancing an internal pipeline of precision genetic medicines focused on autoimmune disease and oncology, led by BRZ-101, a tolerance-inducing candidate for Type 1 diabetes. GenEdit rebranded to BreezeBio in February 2026 alongside a $60M Series B, and has established platform partnerships with Roche's Genentech and Sarepta Therapeutics. This is a therapeutics company with no public developer API, SDK, or developer portal; the profile captures its identity and domain-security posture.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles BreezeBio (formerly GenEdit) the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — BreezeBio (formerly GenEdit) scores 11.9/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile BreezeBio (formerly GenEdit)
Each block below is one kind of artifact we hold for BreezeBio (formerly GenEdit). For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for BreezeBio (formerly GenEdit) — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/geneditbio · machine-readable index on apis.io